Skip to main content
Clinical Trials/NCT04703998
NCT04703998
Completed
Not Applicable

Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma. Prospective Randomized Controlled Trial.

Hospital Italiano de Buenos Aires1 site in 1 country103 target enrollmentJanuary 3, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rotator Cuff Tears
Sponsor
Hospital Italiano de Buenos Aires
Enrollment
103
Locations
1
Primary Endpoint
Comparison of re-tear rates between groups.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Purpose: To assess whether the use of platelet-rich plasma used as an adjuvant to arthroscopic rotator cuff repairs modify the rate of re-tears (measured by MRI) compared to a control group that only underwent the isolated arthroscopic repair. Hypothesis: Platelet rich plasma used as an adjuvant to arthroscopic rotator cuff repairs decrease the rate of retears.

Detailed Description

Platelet-rich plasma used as an adjuvant to arthroscopic rotator cuff repairs modify the rate of re-tears (measured by MRI) compared to a control group that only underwent the isolated arthroscopic repair.

Registry
clinicaltrials.gov
Start Date
January 3, 2021
End Date
September 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

LUCIANO ANDRES ROSSI

Pincipal investigator

Hospital Italiano de Buenos Aires

Eligibility Criteria

Inclusion Criteria

  • Adults between 50 and 75 years with a defined complete rotator cuff tear as compatible clinical and confirmation by magnetic resonance imaging (MRI).
  • Minimum of 3 months of failed conservative treatment (anti-inflammatory, physical therapy and infiltration with corticosteroids)

Exclusion Criteria

  • Refusal to participate or informed consent,
  • Revision surgery,
  • Partial repair,
  • Patients with shoulder osteoarthritis\> 2
  • Advanced fat infiltration of the rotator cuff muscles (STAGE 3 or 4)
  • Systemic or rheumatoid arthritis,
  • Uncontrolled diabetes, (patients for whom surgery is contraindicated in the preoperative evaluation by the clinician and anesthesiologist)
  • Acute or chronic infections of the shoulder to be operated on
  • Ongoing cancer chemotherapy therapies
  • Sepsis, septic arthritis, osteomyelitis or other ongoing infectious processes;

Outcomes

Primary Outcomes

Comparison of re-tear rates between groups.

Time Frame: 6 months

Postoperative MRI to assess the structural integrity of the repaired rotator cuff.

Secondary Outcomes

  • Number of Participants With Treatment-Related Adverse Events(3, 6, and 12 months)
  • Change From baseline in shoulder functional scores at 3, 6 and 12 months(baseline, 3, 6, and 12 months)
  • Change From baseline in pain at 3, 6 and 12 months(baseline, 3, 6, and 12 months)

Study Sites (1)

Loading locations...

Similar Trials